In that study, the authors identified 62 carriers of truncating BARD1 mutations in 58,728 women with breast cancer compared to 32 carriers in 52,976 controls (OR = 2.09; 95% CI, 1.35 to 3.23; p = 0.0001). This evidence concerns the gene BARD1 and breast carcinoma.